全部产品

首页 / 常见产品 / 全部产品

CAS:2254100-49-5|Osimertinib-13C,d3

  • 产品货号:DT2025060264
  • 发布时间:2025-05-29
  • 产品CAS :2254100-49-5
  • 产品规格:mg(更多包装需求请咨询客服)
  • 产品纯度:≥98%
  • 产品货期:现货下单后48小时内发货,定制产品4-8周。
  • 运输条件:顺丰常规运输
询价
产品详情

货号:DT2025060264
CAS:2254100-49-5
规格:mg(更多包装需求请咨询客服)
纯度:≥98%
生产商:试剂家

生物活性:Osimertinib-13C,d3 is the deuterium and 13C labeled Osimertinib. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively.
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Osimertinib-13C,d3 相关抗体:
c-Fos Antibody
Caveolin-1 Antibody
Phospho-EGFR (Tyr1068) Antibody
Phospho-EGFR (Tyr1173) Antibody
c-Fos Antibody (YA506)
EGF Antibody
EGFR Antibody
EGR1 Antibody
Phospholipase C gamma 1 Antibody
Phospho-EGFR (Tyr1068) Antibody (YA204)
HER2 Antibody
EGFR Antibody (YA775)
HER2 Antibody (YA771)
ErbB 4 Antibody
Phospho-EGFR (Tyr1092) Antibody
TGF alpha Antibody
HBEGF Antibody (YA1801)
ErbB 3 Antibody
GRB7 Antibody (YA1165)
分子量:503.62
Formula:C2713CH30D3N7O2
CAS 号:2254100-49-5
非标记 CAS:1421373-65-0
性状:固体
颜色:White to off-white
中文名称:奥斯替尼 13C,d3;奥希替尼 13C,d3
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:4°C, protect from light, stored under nitrogen
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
纯度 & 产品资料
纯度: 99.14%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.;Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third
 [Content Brief]

常见基团 common groups
Online message

在线留言

欢迎您访问“试剂家 | 纳米靶向科研平台”官方网站,请留下您的需求,我们会派专业人员及时与您联系,并为您提供相应的产品方案。

* 咨询产品
* 您的姓名
* 联系电话
留言内容
验证码
Related Products

相关产品